Related Experiment Video
Updated: Apr 18, 2026
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children
Hossein Saneian1, Zahra Pourmoghaddas1, Hamidreza Roohafza2
1Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Insights
A synbiotic containing Bacillus coagulans and FOS showed effectiveness in treating childhood functional abdominal pain (FAP). This intervention improved pain scores in children, suggesting potential as a therapeutic option for FAP.
Area of Science:
- Pediatric Gastroenterology
- Microbiome Research
- Functional Gastrointestinal Disorders
Background:
- Probiotics are recognized for treating functional gastrointestinal disorders in adults.
- Limited research exists on probiotic efficacy for functional abdominal pain (FAP) in pediatric populations.
Purpose of the Study:
- To evaluate the effectiveness of a specific synbiotic formulation in managing childhood functional abdominal pain (FAP).
Main Methods:
- A randomized trial involving 115 children (aged 6-18) with FAP.
- Participants received either a synbiotic (Bacillus coagulans + FOS) or placebo twice daily for four weeks.
- Treatment response was defined by a significant reduction in self-rated pain scores or absence of pain, with a 12-week follow-up.
Main Results:
- The synbiotic group demonstrated a higher response rate (60%) compared to placebo (39.5%) immediately after the four-week treatment (P=0.044).
- No significant differences in response rates were observed at the 12-week follow-up (64.4% vs. 53.4%, P=0.204).
- Synbiotic use and baseline pain severity were identified as predictors of treatment response.
Conclusions:
- The synbiotic formulation containing Bacillus coagulans and FOS shows promise for treating childhood functional abdominal pain (FAP).
- Further clinical trials are warranted to confirm these findings and explore long-term efficacy.
Aim:
We evaluated the effectiveness of a synbiotic in the treatment of childhood functional abdominal pain (FAP).
Background:
Probiotics are effective in the treatment of functional gastrointestinal disorders in adult patients, but there is lack of information in children.
Patients And Methods:
Children with FAP, based on the Rome III criteria (n = 115, aged 6-18 years), were randomized to receive either synbiotic (Bacillus coagulans, Unique IS-2, 150 million spore plus FOS, 100 mg) twice daily or placebo for four weeks. Treatment response was defined as ≥ 2-point reduction in the 6-point self-rated pain scale or "no pain". Physician-rated global severity and improvement were also evaluated. Patients were followed for a total of 12 weeks.
Results:
Eighty-eight patients completed the trial (45 with synbiotic). Response rate was higher with synbiotic than placebo after medication (60% vs. 39.5%, P = 0.044), but was not different between the two groups at week 12 (64.4% vs. 53.4%, P = 0.204). Difference between the two groups regarding the physician-rated global severity over the study period was not statistically significant (z = -1.87, P = 0.062). There was no significant difference between the two groups in physician-rated global improvement (week 4, P = 0.437; week 12, P = 0.111). Receiving synbiotic (OR 2.608, 95% CI: 1.01-6.68) and baseline pain score (OR 2.21, 95% CI: 1.19-4.10) were predictors of treatment response after medication.
Conclusion:
The synbiotic containing Bacillus coagulans and FOS seems to be effective in the treatment of childhood FAP. Further trials are recommended in this regard.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Related Concept Videos
01:22Probiotics
01:21Drugs for Treatment of Constipation-Predominant IBS
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:23Irritable Bowel Syndrome
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...